These are longitudinal data from a single clinical trial in schizophrenia, prepared for use in the single-trial setting. A total of 453 patients were included in the data set. Patients' schizophrenia symptoms were measured using the PANSS and BPRS at baseline (time 0) and at weeks 1, 2, 4, 6, and 8 after the start of treatment. There were two treatment conditions: haloperidol (control,226 patients) and risperidone (treatment, 227 patients).
Schizo_PANSS_BPRSA data frame with 4868 rows and 9 variables:
The anonymized patient ID.
The treatment indicator, coded as 0 = control/haloperidol and 1 = treatment/risperidone.
The assessment week, with values 0, 1, 2, 4, 6, and 8.
The endpoint indicator, either BPRS or PANSS.
The observed endpoint value at the corresponding assessment week.
The log-transformed observed endpoint value.
The assessment week represented as a numeric time variable.
The baseline value of the corresponding endpoint, measured at time 0.
The log-transformed baseline value of the corresponding endpoint, measured at time 0.